BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36971070)

  • 1. In Situ Formed ROS-Responsive Hydrogel with STING Agonist and Gemcitabine to Intensify Immunotherapy against Pancreatic Ductal Adenocarcinoma.
    Wang M; Hu Q; Huang J; Zhang F; Yao Z; Shao S; Zhao X; Liang T
    Adv Healthc Mater; 2023 Aug; 12(20):e2203264. PubMed ID: 36971070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precise Photodynamic Therapy by Midkine Nanobody-Engineered Nanoparticles Remodels the Microenvironment of Pancreatic Ductal Adenocarcinoma and Potentiates the Immunotherapy.
    Qu C; Yuan H; Tian M; Zhang X; Xia P; Shi G; Hou R; Li J; Jiang H; Yang Z; Chen T; Li Z; Wang J; Yuan Y
    ACS Nano; 2024 Feb; 18(5):4019-4037. PubMed ID: 38253029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of a STING Agonist and Photothermal Therapy Using Chitosan Hydrogels for Cancer Immunotherapy.
    Chen C; Hu M; Cao Y; Zhu B; Chen J; Li Y; Shao J; Zhou S; Shan P; Zheng C; Li Z; Li Z
    Biomacromolecules; 2023 Jun; 24(6):2790-2803. PubMed ID: 37125731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma.
    Wu L; Zhang F; Chen X; Wan J; Wang Y; Li T; Wang H
    ACS Appl Mater Interfaces; 2020 Jan; 12(3):3327-3340. PubMed ID: 31872760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
    Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
    Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.
    Koikawa K; Kibe S; Suizu F; Sekino N; Kim N; Manz TD; Pinch BJ; Akshinthala D; Verma A; Gaglia G; Nezu Y; Ke S; Qiu C; Ohuchida K; Oda Y; Lee TH; Wegiel B; Clohessy JG; London N; Santagata S; Wulf GM; Hidalgo M; Muthuswamy SK; Nakamura M; Gray NS; Zhou XZ; Lu KP
    Cell; 2021 Sep; 184(18):4753-4771.e27. PubMed ID: 34388391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy.
    Principe DR; Narbutis M; Kumar S; Park A; Viswakarma N; Dorman MJ; Kamath SD; Grippo PJ; Fishel ML; Hwang RF; Thummuri D; Underwood PW; Munshi HG; Trevino JG; Rana A
    Cancer Res; 2020 Aug; 80(15):3101-3115. PubMed ID: 32238357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of STING in the pancreatic tumor microenvironment: A novel therapeutic opportunity.
    Chamma H; Vila IK; Taffoni C; Turtoi A; Laguette N
    Cancer Lett; 2022 Jul; 538():215694. PubMed ID: 35489447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing pancreatic ductal adenocarcinoma (PDAC) therapy with targeted carbon nano-onion (CNO)-mediated delivery of gemcitabine (GEM)-derived prodrugs.
    Bartkowski M; Bincoletto V; Salaroglio IC; Ceccone G; Arenal R; Nervo S; Rolando B; Riganti C; Arpicco S; Giordani S
    J Colloid Interface Sci; 2024 Apr; 659():339-354. PubMed ID: 38176243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.
    Jiang H; Hegde S; Knolhoff BL; Zhu Y; Herndon JM; Meyer MA; Nywening TM; Hawkins WG; Shapiro IM; Weaver DT; Pachter JA; Wang-Gillam A; DeNardo DG
    Nat Med; 2016 Aug; 22(8):851-60. PubMed ID: 27376576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.
    Zhao T; Ren H; Jia L; Chen J; Xin W; Yan F; Li J; Wang X; Gao S; Qian D; Huang C; Hao J
    Oncotarget; 2015 Feb; 6(4):2250-62. PubMed ID: 25544770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs.
    Qi R; Bai Y; Li K; Liu N; Xu Y; Dal E; Wang Y; Lin R; Wang H; Liu Z; Li X; Wang X; Shi B
    Drug Resist Updat; 2023 May; 68():100960. PubMed ID: 37003125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Ma L; Fan Z; Du G; Wang H
    Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy.
    Bhoopathi P; Mannangatti P; Das SK; Fisher PB; Emdad L
    Adv Cancer Res; 2023; 159():285-341. PubMed ID: 37268399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation.
    Ju HQ; Gocho T; Aguilar M; Wu M; Zhuang ZN; Fu J; Yanaga K; Huang P; Chiao PJ
    Mol Cancer Ther; 2015 Mar; 14(3):788-98. PubMed ID: 25527634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma.
    Matsushita K; Okuda T; Mori S; Konno M; Eguchi H; Asai A; Koseki J; Iwagami Y; Yamada D; Akita H; Asaoka T; Noda T; Kawamoto K; Gotoh K; Kobayashi S; Kasahara Y; Morihiro K; Satoh T; Doki Y; Mori M; Ishii H; Obika S
    ChemMedChem; 2019 Aug; 14(15):1384-1391. PubMed ID: 31207139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis.
    Ho TTB; Nasti A; Seki A; Komura T; Inui H; Kozaka T; Kitamura Y; Shiba K; Yamashita T; Yamashita T; Mizukoshi E; Kawaguchi K; Wada T; Honda M; Kaneko S; Sakai Y
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33188035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of pancreatic cancer microenvironment by an intelligent gemcitabine@nanogel system via in vitro 3D model for promoting therapeutic efficiency.
    Chen D; Zhu X; Tao W; Kong Y; Huag Y; Zhang Y; Liu R; Jiang L; Tang Y; Yu H; Hao Q; Yang X; Zou H; Chen J; Lu Y; Zhang H; Li W
    J Control Release; 2020 Aug; 324():545-559. PubMed ID: 32504777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Gifford JB; Huang W; Zeleniak AE; Hindoyan A; Wu H; Donahue TR; Hill R
    Mol Cancer Ther; 2016 May; 15(5):1043-52. PubMed ID: 26939701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of hyperbaric oxygenation and gemcitabine on apoptosis of pancreatic ductal tumor cells in vitro.
    Bosco G; Guizzon L; Yang Z; Camporesi E; Casarotto A; Bosio C; Mangar D; Chen C; Cannato M; Toniolo L; Garetto G; Nasole E; Bassi C
    Anticancer Res; 2013 Nov; 33(11):4827-32. PubMed ID: 24222119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.